As­traZeneca pre­pares to live with the IRA, shift­ing fo­cus of ar­gu­ments to or­phan drug changes

NEW YORK — As­traZeneca may be get­ting ready to live with the In­fla­tion Re­duc­tion Act.

On Fri­day morn­ing, CEO Pas­cal So­ri­ot told re­porters that the drug­mak­er is most fo­cused on get­ting the 2022 law ad­just­ed, not in­val­i­dat­ed. His com­ments are the most di­rect yet from a ma­jor phar­ma CEO about a fu­ture in which the IRA is not ful­ly over­turned by the courts, as sev­er­al drug­mak­ers have sued to try and do.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER